Indo-European Consortium for Next Generation Influenza Vaccine Innovation

Project Information

INCENTIVE

Grant agreement ID: 874866

DOI

10.3030/874866

Project closed

EC signature date 13 December 2019

Start date 1 August 2020

End date 31 January 2026

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost

€ 19 965 992,50

EU contribution

€ 9 974 293,75

Coordinated by

HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH
Germany

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Documents, reports (4)

INCENTIVE-QIV-1,2,3 (EU) and QIV-1 (India): Study results posted in the study registry

Safety and preliminary immunogenicity results posted on the study registry. Timelines if/when final posting of results is scheduled after end of funding period will be included.

INCENTIVE-QIV: Registration of the clinical trial in the trial registry

Study registered at a WHO or ICMJapproved registry

Development and annual update of INCENTIVE dissemination and exploitation plan delivered

Plan and annual update on dissemination activities and IP exploitation.

A blueprint for rolling out stratified influenza vaccination programs, in order to optimize / maximize efficiency and effectiveness taking into account acceptability, affordability and accessibility issues

Development of blueprint for the rollout of stratified influenza vaccination program.

Websites, patent fillings, videos etc. (1)

Project presentation prepared, website launched and communication plan developed

Setting up consortium website public and secured intranet Communication plan regulating the consortium communication

Publications

Peer reviewed articles (14)

Human Organotypic Airway and Lung Organoid Cells of Bronchiolar and Alveolar Differentiation Are Permissive to Infection by Influenza and SARS-CoV-2 Respiratory Virus

Author(s): Camilla Tvedt Ekanger, Fan Zhou, Dana Bohan, Maria Lie Lotsberg, Maria Ramnefjell, Laurence Hoareau, Gro Vatne Røsland, Ning Lu, Marianne Aanerud, Fabian Gärtner, Pirjo Riitta Salminen, Mariann Bent
Published in: Frontiers in Cellular and Infection Microbiology, Issue 12, 2022, Page(s) 841447, ISSN 2235-2988
Publisher: Frontiers Media S. A.
DOI: 10.3389/fcimb.2022.841447

Seasonal influenza vaccination expands hemagglutinin-specific antibody breadth to older and future A/H3N2 viruses

Author(s): Nina Urke Ertesvåg, Rebecca Jane Cox, Sarah Larteley Lartey, Kristin G-I Mohn, Karl Albert Brokstad, Mai-Chi Trieu
Published in: npj Vaccines, Issue 7, 2022, Page(s) 490, ISSN 2059-0105
Publisher: Springer Science and Business Media LLC
DOI: 10.1038/s41541-022-00490-0

Intranasal administration of octavalent next-generation influenza vaccine elicits protective immune responses against seasonal and pre-pandemic viruses

Author(s): Naoko Uno, Thomas Ebensen, Carlos A. Guzman, Ted M. Ross
Published in: Journal of Virology, Issue 98, 2024, ISSN 0022-538X
Publisher: American Society for Microbiology
DOI: 10.1128/jvi.00354-24

Effects of repeated influenza vaccination and infection on durable seroprotection in healthcare workers

Author(s): Mai-Chi Trieu, Amit Bansal, Marianne Sævik, Sonja Ljostveit, Åsne Jul-Larsen, Rebecca Jane Cox
Published in: npj Vaccines, Issue 10, 2025, Page(s) 1259, ISSN 2059-0105
Publisher: Springer Science and Business Media LLC
DOI: 10.1038/s41541-025-01259-x

Influenza hemagglutinin and neuraminidase multivalent vaccine elicits broader protective immune responses compared to vaccine formulations composed of hemagglutinin or neuraminidase

Author(s): Naoko Uno, Ted M. Ross
Published in: Human Vaccines & Immunotherapeutics, Issue 21, 2026, Page(s) 259961, ISSN 2164-5515
Publisher: Landes Bioscience
DOI: 10.1080/21645515.2025.2599611

Repeated Influenza Vaccination Boosts and Maintains H1N1pdm09 Neuraminidase Antibody Titers

Author(s): Lena Hansen, Fan Zhou, Håkon Amdam, Mai-Chi Trieu, Rebecca Jane Cox
Published in: Frontiers in Immunology, Issue 12, 2021, Page(s) 748264, ISSN 1664-3224
Publisher: Frontiers Media SA
DOI: 10.3389/fimmu.2021.748264

Impact of Pre-Existing Immunity and Age on Antibody Responses to Live Attenuated Influenza Vaccine

Author(s): Lukas Hoen, Sarah Lartey, Fan Zhou, Rishi D. Pathirana, Florian Krammer, Kristin G -I Mohn, Rebecca J. Cox, Karl A. Brokstad
Published in: Vaccines, Issue 12, 2025, Page(s) 864, ISSN 2076-393X
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/vaccines12080864

Matrix M Adjuvanted H5N1 Vaccine Elicits Broadly Neutralizing Antibodies and Neuraminidase Inhibiting Antibodies in Humans That Correlate With In Vivo Protection

Author(s): Fan Zhou, Lena Hansen, Gabriel Pedersen, Gunnveig Grødeland, Rebecca Cox
Published in: Frontiers in Immunology, Issue 12, 2021, Page(s) 747774, ISSN 1664-3224
Publisher: Frontiers Media SA
DOI: 10.3389/fimmu.2021.747774

Next Generation Influenza Vaccines: Looking into theCrystal Ball

Author(s): Carlos Alberto Guzmán
Published in: Vaccines, 2020, ISSN 2076-393X
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/vaccines8030464

DNA vaccines targeting hemagglutinin from 18 subtypes of influenza A virus to antigen-presenting cells confer broad protection

Author(s): Ane Marie Anderson, Elias Tjärnhage, Daniëla Maria Hinke, Ranveig Braathen, Gunnveig Grodeland, Bjarne Bogen
Published in: Molecular Therapy Nucleic Acids, Issue 37, 2026, Page(s) 102814, ISSN 2162-2531
Publisher: Nature Publishing Group
DOI: 10.1016/j.omtn.2025.102814

Point-of-Care Influenza Testing Impacts Clinical Decision, Patient Flow, and Length of Stay in Hospitalized Adults

Author(s): Elisabeth B Fjelltveit, Rebecca J Cox, Jørgen Østensjø, Bjørn Blomberg, Marit H Ebbesen, Nina Langeland, Kristin G I Mohn
Published in: The Journal of Infectious Diseases, Issue 226, 2022, Page(s) 97-108, ISSN 0022-1899
Publisher: University of Chicago Press
DOI: 10.1093/infdis/jiaa690

Safety, Immunogenicity, Efficacy and Effectiveness of Inactivated Influenza Vaccines in Healthy Pregnant Women and Children Under 5 Years: An Evidence-Based Clinical Review

Author(s): Amit Bansal, Mai-Chi Trieu, Kristin G. I. Mohn, Rebecca Jane Cox
Published in: Frontiers in Immunology, Issue 12, 2021, Page(s) 744774, ISSN 1664-3224
Publisher: Frontiers Media SA
DOI: 10.3389/fimmu.2021.744774

Multivalent next generation influenza virus vaccines protect against seasonal and pre-pandemic viruses

Author(s): Naoko Uno, Ted M. Ross
Published in: Scientific Reports, Issue 14, 2024, ISSN 2045-2322
Publisher: Nature Publishing Group
DOI: 10.1038/s41598-023-51024-0

Prospects and Challenges in the Development of Universal Influenza Vaccines

Author(s): Anders Madsen, Rebecca Jane Cox
Published in: Vaccines, Issue 8, 2025, Page(s) 361, ISSN 2076-393X
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/vaccines8030361